NCT03871361

Abatacept in Patients With Birdshot HLA A29 Uveitis

Abatacept in Patients With Birdshot HLA A29 Uveitis: A Phase II Prospective 0pen Label Interventional Proof-of-Concept Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Universitaire Ziekenhuizen KU Leuven · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To assess the efficacy and safety of Abatacept as an immunosuppressive treatment in Birdshot uveitis. The primary objective is to test the efficacy to suppress inflammation in active Birdshot uveitis patients, using quantitative and qualitative measurements of visual function.

Detailed description

To assess the efficacy and safety of Abatacept as an immunosuppressive treatment in Birdshot uveitis. The primary objective is to assess the efficacy to suppress active uveitis in Birdshot uveitis and to induce inflammatory remission during the 1 year treatment and after 2 years of treatment. Treatment efficacy will be assessed, using quantitative and qualitative measurements of visual function. In this trial we will also assess the utility of quantitative outcome measures in detecting disease activity.

Conditions

• Eye Diseases
• Uveitis

Interventions

Type	Name	Description
DRUG	Abatacept 125 MG/ML Prefilled Syringe	Abatacept 125 MG/ML Prefilled Syringe \[Orencia\] weekly

Timeline

• Start date: 2019-04-01
• Primary completion: 2022-01-01
• Completion: 2023-12-01
• First posted: 2019-03-12
• Last updated: 2023-12-04

Locations

1 site across 1 country: Belgium